Illumina
ILMN · NASDAQ
Supply-chain layerShort-read sequencing and informatics
Illumina supplies sequencing instruments, consumables, and informatics that generate a large share of the standardized genomic data used in biological model development.
Supply-chain research brief
AI Biotech Infrastructure
Map sequencing, automation, instruments, bioprocessing, compute, data, and scale-up infrastructure for AI-native biotech.
Market map
Where constraints can shape the market
AI-native biology is constrained by the cost, quality, and throughput of experimental feedback. Models need sequence and assay data, automated laboratories, reliable instruments, reagents, sample handling, bioprocessing, and compute. A digital prediction has limited value until a physical experiment can validate it and a process can reproduce it at scale.
The directory separates sequencing and omics, laboratory automation, bioprocessing consumables, cloud and data infrastructure, AI drug-discovery platforms, CRO/CDMO scale-up, and synthetic-biology screening. This distinguishes enabling infrastructure from drug developers whose economics remain tied to individual clinical assets.
Evidence is weighted by maturity: an official product or platform page supports technical relevance; a named collaboration supports workflow adoption; reported instrument placements, consumables growth, backlog, or manufacturing agreements provide stronger economic validation. Unreported AI-biotech revenue is not presented as fact.
Research universe
Supply-chain layers we track
- Sequencing & Omics4 tracked companies
- Lab Automation & Instruments7 tracked companies
- Bioprocessing & Consumables4 tracked companies
- Cloud, Compute & Data4 tracked companies
- AI Drug Discovery Platforms3 tracked companies
- CRO, CDMO & Scale-up3 tracked companies
- Synthetic Biology & Screening2 tracked companies
Public preview
Five companies in the research universe
Examples are selected by the current research-priority ordering. Scores, risks, evidence, and the complete supplier map remain in the full directory.
Lonza Group
LONN · SIX
Supply-chain layerBiologics development and manufacturing
Lonza provides development and manufacturing capacity that converts digitally discovered candidates into reproducible clinical and commercial supply.
Samsung Biologics
207940 · KRX
Supply-chain layerLarge-scale biologics CDMO
Samsung Biologics supplies large-scale biologics manufacturing capacity, a downstream qualification bottleneck after AI-enabled discovery identifies a viable molecule.
Sartorius
SRT · Xetra
Supply-chain layerSingle-use bioprocessing and laboratory systems
Sartorius provides single-use bioprocessing systems and laboratory tools needed to translate experimental hits into repeatable biological production.
10x Genomics
TXG · NASDAQ
Supply-chain layerSingle-cell and spatial biology
10x Genomics supplies single-cell and spatial workflows that create high-dimensional training and validation data for biological models.
Full research access
Open all 27 companies, scores, risks, and sources.
Verify your email to use the filterable directory and review the complete evidence-backed research set.
Questions
How to read this market
What is the core AI-biotech bottleneck?
The experiment loop: generating standardized biological data, automating assays, learning from results, and translating a candidate into reproducible manufacturing.
Why include diversified tool vendors?
A diversified instrument or consumables supplier can control a critical workflow despite low pure-play exposure, so bottleneck relevance is scored separately.
Are AI drug developers infrastructure companies?
Only when their platforms generate reusable data or workflow capacity. Pipeline value and platform value are separated in the thesis and risk assessment.